Reactions and enzymes in the metabolism of drugs and other xenobiotics

Drug Discovery Today

Volumn 17, Issue 11-12, 2012, Pages 549-560

  Testa, Bernard ^a   Pedretti, Alessandro ^b   Vistoli, Giulio ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLITE; ENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDROLASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; METHYLTRANSFERASE; MYELOPEROXIDASE; OXIDOREDUCTASE; PARACETAMOL; PEROXIDASE; PROSTAGLANDIN SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SULFOTRANSFERASE; TRANSFERASE; UNSPECIFIC MONOOXYGENASE; XANTHINE OXIDASE; XENOBIOTIC AGENT;

ACETYLATION; CATALYSIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME SUBSTRATE; GLYCOSYLATION; HUMAN; HYDROLYSIS; NONHUMAN; OXIDATION REDUCTION REACTION; REVIEW; STEREOISOMERISM; XENOBIOTIC METABOLISM;

ANIMALS; BIOCHEMICAL PROCESSES; DRUG DISCOVERY; ENZYMES; HUMANS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY; XENOBIOTICS;

EID: 84861646776     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.01.017     Document Type: Review

References (64)

1. R.T. Williams Detoxication Mechanisms 1947 Chapman & Hall
2. nd edn 1959 Chapman & Hall
3. International Society for the Study of Xenobiotics. http://www.issx.org (accessed 4.01.11)
4. D. Zhang Drug Metabolism in Drug Design and Development 2008 Wiley-Interscience
5. L.G. Yengi The evolving role of drug metabolism in drug discovery and development Pharm. Res. 24 2007 842 858
6. B. Testa, and S.D. Krämer The biochemistry of drug metabolism. Part 5: Metabolism and bioactivity Chem. Biodivers. 6 2009 591 684
7. K.K. Midha The role of metabolites in bioequivalence Pharm. Res. 21 2004 1331 1344
8. A. Fura Discovering drugs though biological transformation: role of pharmacologically active metabolites in drug discovery J. Med. Chem. 47 2004 4339 4351
9. J. Raito Prodrugs: design and clinical applications Nat. Rev. Drug Discov. 7 2008 255 270
10. B. Testa Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps Curr. Opin. Chem. Biol. 13 2009 338 344
11. W. Tang, and A.Y.H. Lu Metabolic bioactivation and drug-related adverse effects: currents status and future directions from a pharmaceutical research perspective Drug Metab. Rev. 42 2010 225 249
12. S. Kumar Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions Curr. Opin. Drug Discov. Dev. 11 2008 43 52
13. G.A. Doss, and T.A. Baillie Addressing metabolic activation as an integral component of drug design Drug Metab. Rev. 38 2006 641 649
14. C.E.C.A. Hop Importance of early assessment of bioactivation in drug discovery Annu. Rep. Med. Chem. 41 2011 369 381
15. rd edn 2008 Academic Press 674 696
16. nd edn) (Taylor, J.B. and Triggle, D.J., eds.), pp. 193-214, Elsevier
17. nd edn) (Taylor, J.B. and Triggle, D.J., eds.), pp. 215-229, Elsevier
18. B.K. Park Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective Chem. Res. Toxicol. 11 1998 969 988
19. F.P. Guengerich, and J.S. MacDonald Applying mechanisms of chemical toxicity to predict drug safety Chem. Res. Toxicol. 20 2007 344 369
20. A.S. Kalgutkar A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6 2005 161 225
21. H. Kubinyi Drug research: myths, hype and reality Nat. Rev. Drug Discov. 2 2003 665 668
22. J. Orloff The future of drug development: advancing clinical trial design Nat. Rev. Drug Discov. 8 2009 949 957
23. N.A. Tamimi, and P. Ellis Drug development: from concept to marketing! Nephron Clin. Pract. 113 2009 c125 c131
24. I. Cavero Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations Exp. Opin. Drug Saf. 8 2009 627 647
25. J. Wang Comprehensive assessment of ADMET risks in drug discovery Curr. Pharm. Des. 15 2009 2195 2219
26. Y.Z. Shu Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery AAPS J. 10 2008 178 192
27. A.S. Kalgutkar, and M.T. Didiuk Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem. Biodivers. 6 2009 2115 2137
28. A.S. Bass Exploratory drug safety: a discovery strategy to reduce attrition in development J. Pharmacol. Toxicol. Methods 60 2009 69 78
29. B. Wen, and W.L. Fitch Analytical strategies for the screening and evaluation of chemically reactive drug metabolites Exp. Opin. Drug Metab. Toxicol. 5 2009 39 55
30. D. Cook Improving drug safety using computational biology IDrugs 13 2005 85 89
31. S. Ekins Computational prediction of human drug metabolism Exp. Opin. Drug Metab. Toxicol. 1 2005 303 324
32. H. van de Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2 2003 192 204
33. A. Oliva Bioinformatics modernization and the critical path to improved benefit-risk assessment of drugs Drug Inform. J. 42 2008 273 279
34. R.D. Saiakhov, and G. Klopman MultiCASE expert systems and the REACH initiative Toxicol. Mech. Methods 18 2008 159 175
35. C.A. Marchant In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows Meteor. Vitic. Toxicol. Mech. Methods 18 2008 177 187
36. B. Testa Predicting drug metabolism: concepts and challenges Pure Appl. Chem. 76 2004 907 914
37. S. Ekins In silico pharmacology for drug discovery: applications to targets and beyond Br. J. Pharmacol. 152 2007 21 37
38. B. Testa Drug metabolism for the perplexed medicinal chemist Chem. Biodivers. 6 2009 2055 2070
39. B. Testa, and S.D. Krämer The Biochemistry of Drug Metabolism - Volume 1: Principles, Redox Reactions, Hydrolyses 2008 Verlag Helvetica Chimica Acta/Wiley-VCH
40. B. Testa, and S.D. Krämer The Biochemistry of Drug Metabolism - Volume 2: Conjugations, Consequences of Metabolism, Influencing Factors 2010 Verlag Helvetica Chimica Acta/Wiley-VCH
41. B. Testa Nonenzymatic contributions to xenobiotic metabolism Drug Metab. Rev. 13 1982 25 50
42. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB). Enzyme Nomenclature. http://www.chem.qmul.ac.uk/ iubmb/enzyme
43. 3: measurement of futile metabolic deacetylation via HPLC/MS-SPE-NMR and HPLC-ToF-MS Xenobiotica 36 2006 615 629
44. B. Testa, and P. Jenner Novel metabolites produced by functionalization reactions: chemistry and toxicology Drug Metab. Rev. 7 1978 325 369
45. th edn 2010 Wiley 127 166
46. S. Rendic Summary of information on human CYP enzymes: human P450 metabolism data Drug Metab. Rev. 34 2002 83 448
47. F.P. Guengerich, and S. Rendic Update information on drug metabolism systems - 2009, Part II: Summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters Curr. Drug Metab. 11 2010 4 84
48. J.A. Williams Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokineitc explanation for typically observed low exposure (AUCi/AUC) ratios Drug Metab. Dispos. 32 2004 1201 1208
49. L.C. Wienkers, and T.G. Heath Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discov. 4 2005 825 833
50. A. Albert The behaviour of foreign substances in the human body Trends Pharmacol. Sci. 8 1987 258 261
51. B.N. Ames, and M. Profet Nature's pesticides Nat. Toxins 1 1992 2 3
52. W.B. Jakoby, and D.M. Ziegler The enzymes of detoxication J. Biol. Chem. 265 1990 20715 20718
53. W.R. Jondorf Drug-metabolizing enzymes as evolutionary probes Drug Metab. Rev. 12 1981 379 430
54. F.J. Gonzalez, and D.W. Nebert Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation Trends Genet. 6 1990 182 186
55. D.A. Smith, and D. Dalvie Why do metabolites circulate? Xenobiotica 42 2012 107 126
56. T.S. Eliot Little Gidding Collected Poems 1974 Faber and Faber London pp. 214-223
57. W.R. Jondorf Drug metabolism and drug toxicity: some evolutionary considerations P. Jenner, B. Testa, Concepts in Drug Metabolism, Part B 1981 Dekker 305 376
58. P.F. Dodds Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid biosynthesis Prog. Lipid Res. 34 1995 219 247
59. B. Testa Predicting drug metabolism - an evaluation of the expert system METEOR Chem. Biodivers. 2 2005 872 885
60. S. Ekins Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites Drug Metab. Dispos. 29 2001 936 944
61. G. Cruciani MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist J. Med. Chem. 48 2005 6970 6979
62. M.J. de Groot Designing better drugs: predicting cytochrome P450 metabolism Drug Discov. Today 11 2006 601 606
63. G. Caron Predicting the oxidative metabolism of statins. An application of the MetaSite algorithm Pharm. Res. 24 2007 480 501
64. W.G. Button Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics J. Chem. Inf. Model. 43 2003 1371 1377